ClinicalTrials.gg
RecruitingNCT07202546Updated Nov 12, 2026

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

A Phase 2 interventional study of VH4524184 and Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets in HIV Infections, sponsored by ViiV Healthcare. Recruiting at 125 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 12, 2026Site recruiting status changedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
186
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.

Planned enrollment
70th of 210
186 · median 82
Started
2026
with 9 others
Phase 2
48 of 266
2 open now
Primary completion
2027-10
later than 17 of 26 live
Registered
257th of 266
by date

Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 70th largest by planned enrollment of the 210 interventional ones that give a count, is one of 10 that started in 2026, is one of 48 in phase 2, reaches primary completion later than 17 of the 26 other live ones, and was the 257th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in HIV Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

This clinical study is testing a new medication, VH4524184, to see if it can effectively treat HIV-1 in adults who have never received treatment for their infection. The study is comparing two different doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide (FTC/TAF), to a standard HIV treatment called dolutegravir and lamivudine (DTG/3TC). The purpose of the study is to provide data on the long-term antiviral activity of the VH4524184 and provide information regarding dosing formulation for further evaluations.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Fixed dose combination
  • Antiretroviral
  • Antiviral
  • Naive viremics
  • Innovate
  • VH4524184
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be at least 18 years of age (or older, if required for adults by local regulations) at the time of signing the .
  2. Screening >200 cells/microlitre (µL).
  3. Documented -1 infection and Screening plasma HIV-1 RNA of ≥1000 copies/millilitre (mL). A single repeat of this test is allowed within a single Screening period to determine eligibility.
  4. Treatment-naive: Defined as no ARVs (in combination or monotherapy) received after the diagnosis of HIV-1 infection.
  5. Body weight >=50.0 kilogram (kg) [(110 pounds (lbs)] for participants assigned male at birth and >=45.0 kg (99 lbs) for participants assigned female at birth. within the range 18.5-35.5 kg/m\^2 (inclusive - applies to males and females).
  6. There are no requirements for participants assigned male at birth.
  7. Participants assigned female at birth are eligible to participate if they are not pregnant or breastfeeding and one of the following conditions applies:

    • Is a Participant of non- (PONCBP);OR Is a Participant of childbearing potential (POCBP) and using a contraceptive method with a failure rate of less than (\<) 1% prior to and during the study intervention period, and for at least 1 week after the last dose of VH4524184 plus FTC/TAF FDC, or through the end of study (if in the control arm and never received VH4524184).
    • A POCBP must have a negative pregnancy test at Screening (serum) and on Day 1 (urine) before the first dose of study intervention.
    • If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. Participant with a positive serum test must be excluded.
  8. Capable of giving signed informed consent. Persons who are placed in an institution by order of a public authority or a court are excluded from participation in this study.

Exclusion criteria

Exclusion Criteria:

  1. Participants who are breastfeeding or plan to breastfeed during the study.
  2. Participants with acute infection, evidenced by acute retroviral syndrome (e.g., fever, malaise, fatigue, etc.) and/or evidence of recent (within 3 months) documented viremia without antibody production and/or evidence of recent (within 3 months) documented seroconversion.
  3. Any evidence of an active Centres for Disease Control and Prevention (CDC) Stage 3 disease [CDC 2014], except cutaneous Kaposi's sarcoma not requiring systemic therapy during the study. Historical less than 200 cells/µL are not exclusionary.
  4. Unstable liver disease known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment).
  5. History of cirrhosis with or without viral hepatitis co-infection.
  6. Participants with co-infection will be excluded from the study.
  7. Individuals who are co-infected with HIV and will be excluded Participants diagnosed with syphilis at Screening (i.e., positive syphilis testing) should be treated as per local guidelines and will be eligible to enroll at any time regardless of the stage of disease.
  8. Uncontrolled is excluded, whereas participants who have controlled malignancies may be included in agreement between the investigator and the ViiV Healthcare medical monitor.
  9. Any pre-existing physical, or mental condition (including alcohol or drug abuse) which, in the opinion of the investigator (with or without psychiatric evaluation) or the ViiV Healthcare medical monitor, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
  10. Any condition which, in the opinion of the investigator or the ViiV Healthcare medical monitor, that may interfere with the absorption, distribution, metabolism or excretion of the study interventions or render the participant unable to take oral medication and normal gastrointestinal anatomy or motility or hepatic and/or renal function
  11. CV disease, as defined by history/evidence of congestive heart failure, symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting surgery or percutaneous transluminal coronary angioplasty or any clinically significant cardiac disease.
  12. Participants receiving any protocol-prohibited medication and who are unwilling or unable to switch to an alternate medication.
  13. History of sensitivity to any of the study medications, or their components or drugs of their class, or a history of drug or other allergy that, in the opinion of the investigator or ViiV Healthcare medical monitor, contraindicates their participation.
  14. Current or anticipated need for chronic anti-coagulation with the exception of the use of low dose acetylsalicylic acid (≤325 mg) or hereditary coagulation and disorders such as hemophilia or Von Willebrand Disease.
  15. Treatment with any of the following agents within 60 days of Screening: radiation therapy, cytotoxic chemotherapeutic agents, any systemic immune suppressant.
  16. Treatment with immunomodulating agents (such as systemic , interleukins, interferons) or any agent with known anti-HIV activity (such as hydroxyurea or foscarnet) within 30 days of Day 1.
  17. Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening.
  18. Exposure to an approved vaccine within 14 days prior to Day 1.
  19. Current enrollment or past participation within the last 30 days before signing of consent in any other clinical study involving an study intervention or any other type of medical research
  20. Participants with known or suspected presence of virologic resistance mutations as defined by the Stanford HIV Drug Resistance Database to INSTIs or NRTIs. This determination will be based on local virologic resistance testing, either at Screening or within the 3 months prior to Screening. ViiV Healthcare clinical virologist and/or ViiV Healthcare medical monitor will verify eligibility to this criterion prior to Day 1.
  21. () of \<60 mL/min/1.73 m2 via CKD-EPI race neutral method [Delgado, 2021].
  22. >3 times the (ULN). A single repeat of ALT is allowed within a single screening period to determine eligibility.
  23. Any Grade 4 laboratory abnormality at screening, except for a Grade 4 CPK and lipid abnormalities (e.g., total cholesterol, triglycerides, etc.) will exclude a participant from the study unless the investigator can provide a compelling explanation for the laboratory result(s) and has the assent of the ViiV Healthcare medical monitor. A single repeat of any lab abnormality is allowed within a single screening period to determine eligibility.
  24. Any acute laboratory abnormality at screening which, in the opinion of the investigator, should preclude participation in the study of an investigational compound.
  25. Exclusion criteria for screening (a single repeat is allowed for eligibility determination and will be the screening ECG entered into the eCRF): corrected for heart rate according to Fridericia's formula (QTcF) >450 msec (males) or >470 msec (females); >480 msec for participants with bundle branch block.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
186 participants (estimated)

Study arms

  • Experimental
    VH4524184 Dose A+ FTC / TAF

    Participants receive a daily oral dose of VH4524184 Dose A (Low dose) in combination with a fixed dose containing FTC/TAF starting Day 1 until Month 12.

    Drug: VH4524184 · Drug: Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets

  • Experimental
    VH4524184 Dose B + FTC / TAF

    Participants receive a daily oral dose of VH4524184 Dose B (High dose) in combination with a fixed dose containing FTC / TAF beginning on Day 1 until the Month 12.

    Drug: VH4524184 · Drug: Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets

  • Active comparator
    DTG + 3TC

    Participants receive a daily oral dose of DTG and 3TC (fixed dose combination) from Day 1 through Month 24.

    Drug: Dolutegravir / Lamivudine (DTG/3TC)

  • Experimental
    VH4524184 selected dose + FTC / TAF

    Participants receive a selected dose of VH4524184, combined with FTC/TAF, orally once daily from to Month 12 to Month 24.

    Drug: VH4524184 · Drug: Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets

Interventions

  • Oral tablet will be administered.

  • DrugEmtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets

    Drug page: Emtricitabine tenofovir alafenamide

    Oral table will be administered.

    Also known as: DESCOVY

  • DrugDolutegravir / Lamivudine (DTG/3TC)

    Drug pages: Dolutegravir · Lamivudine

    Oral tablets will be administered.

    Also known as: DOVATO

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Suppression (<50 copies/millilitre) as per FDA Snapshot Methodology

    Time frame: At Month 12

Secondary outcomes

  1. Percentage of Participants Maintaining Plasma HIV-1 RNA Suppression (<50 copies/mL) Based on Observed Laboratory Results

    Time frame: Day 1 to Month 24

  2. Percentage of Participants Achieving Plasma HIV-1 RNA Suppression (<50 copies/ml) as per FDA Snapshot Methodology

    Time frame: Day 1 to Month 24

  3. Change From Baseline in Cluster of Differentiation 4 (CD4+) T-cell Counts

    Blood samples will be collected for assessment of T-cells subsets (CD4+ T-cells count) by flow cytometry.

    Time frame: Day 1 to Month 24

  4. Number of Participants with Any Adverse Event (AE)

    Time frame: Day 1 through the continuation period/end of study (approximately Month 36)

  5. Number of Participants with AEs by Severity

    The severity will be assessed using The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table) Version 2.1 where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening and Grade 5 = Death.

    Time frame: Day 1 through the continuation period/end of study (approximately Month 36)

  6. Number of Participants with AEs Leading to Study Treatment Discontinuation

    Time frame: Day 1 through the continuation period/end of study (approximately Month 36)

  7. Plasma Concentration of VH4524184

    Blood samples will be collected at indicated time point for PK analysis of VH4524184.

    Time frame: Day 1 to Month 24

07

Study locations

124 of 125 sites recruiting
  • GSK Investigational Site
    Bakersfield, California 93309, United States
    Recruiting
  • GSK Investigational Site
    Palm Springs, California 92262, United States
    Recruiting
  • GSK Investigational Site
    West Hollywood, California 90046, United States
    Recruiting
  • GSK Investigational Site
    Aurora, Colorado 80045, United States
    Recruiting
  • GSK Investigational Site
    New Haven, Connecticut 06501, United States
    Recruiting
  • GSK Investigational Site
    Ft. Pierce, Florida 34982-7148, United States
    Recruiting
  • GSK Investigational Site
    Hollywood, Florida 33021, United States
    Recruiting
  • GSK Investigational Site
    Miami, Florida 33136, United States
    Recruiting
  • GSK Investigational Site
    Miami Gardens, Florida 33055-2934, United States
    Recruiting
  • GSK Investigational Site
    Oakland Park, Florida 33334-4434, United States
    Recruiting
  • GSK Investigational Site
    Orlando, Florida 32803-1851, United States
    Recruiting
  • GSK Investigational Site
    Orlando, Florida 32803-5230, United States
    Recruiting
  • GSK Investigational Site
    West Palm Beach, Florida 33409, United States
    Recruiting
  • GSK Investigational Site
    Atlanta, Georgia 30308, United States
    Recruiting
  • GSK Investigational Site
    Macon, Georgia 31201, United States
    Recruiting
  • GSK Investigational Site
    Chicago, Illinois 60637-1443, United States
    Recruiting
  • GSK Investigational Site
    Louisville, Kentucky 40202, United States
    Completed

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    Columbia, Missouri 65212, United States
    Recruiting
  • GSK Investigational Site
    Kansas City, Missouri 64111, United States
    Recruiting
  • GSK Investigational Site
    Omaha, Nebraska 68106-1802, United States
    Recruiting
  • GSK Investigational Site
    Hackensack, New Jersey 07601, United States
    Recruiting
  • GSK Investigational Site
    Newark, New Jersey 07102-1909, United States
    Recruiting
  • GSK Investigational Site
    Albany, New York 12208, United States
    Recruiting
  • GSK Investigational Site
    Manhasset, New York 11030, United States
    Recruiting
  • GSK Investigational Site
    Charlotte, North Carolina 28204, United States
    Recruiting
  • GSK Investigational Site
    Durham, North Carolina 27710-4000, United States
    Recruiting
  • GSK Investigational Site
    Greensboro, North Carolina 27401, United States
    Recruiting
  • GSK Investigational Site
    Wilmington, North Carolina 28401, United States
    Recruiting
  • GSK Investigational Site
    Cincinnati, Ohio 45267, United States
    Recruiting
  • GSK Investigational Site
    Bellaire, Texas 77401, United States
    Recruiting
  • GSK Investigational Site
    Dallas, Texas 75246-2004, United States
    Recruiting
  • GSK Investigational Site
    Houston, Texas 77025, United States
    Recruiting
  • GSK Investigational Site
    Houston, Texas 77030, United States
    Recruiting
  • GSK Investigational Site
    Longview, Texas 75605-2410, United States
    Recruiting
  • GSK Investigational Site
    Seattle, Washington 98104, United States
    Recruiting
  • GSK Investigational Site
    Buenos Aires, 1023, Argentina
    Recruiting
  • GSK Investigational Site
    Buenos Aires, 1427, Argentina
    Recruiting
  • GSK Investigational Site
    Buenos Aires, C1425AGC, Argentina
    Recruiting
  • GSK Investigational Site
    Ciudad Autonoma Buenos Aires, C1002ABJ, Argentina
    Recruiting
  • GSK Investigational Site
    Ciudad Autonoma de Bueno, 1405, Argentina
    Recruiting
  • GSK Investigational Site
    Mar del Plata, B7600FZO, Argentina
    Recruiting
  • GSK Investigational Site
    San Miguel de Tucumán, T4000IHE, Argentina
    Recruiting
  • GSK Investigational Site
    Sydney, New South Wales 2010, Australia
    Recruiting
  • GSK Investigational Site
    Clayton, Victoria 3168, Australia
    Recruiting
  • GSK Investigational Site
    Melbourne, Victoria 3004, Australia
    Recruiting
  • GSK Investigational Site
    Ghent, Oost-Vlaanderen 9000, Belgium
    Recruiting
  • GSK Investigational Site
    Antwerp, 2000, Belgium
    Recruiting
  • GSK Investigational Site
    Brussels, 1000, Belgium
    Recruiting
  • GSK Investigational Site
    Montreal, Quebec H2L 4P9, Canada
    Recruiting
  • GSK Investigational Site
    Montreal, Quebec H4A 3J1, Canada
    Recruiting
  • GSK Investigational Site
    Bordeaux, 33000, France
    Recruiting
  • GSK Investigational Site
    Caen, 14033, France
    Recruiting
  • GSK Investigational Site
    Nantes, 44093, France
    Recruiting
  • GSK Investigational Site
    Nîmes, 30029, France
    Recruiting
  • GSK Investigational Site
    Paris, 75010, France
    Recruiting
  • GSK Investigational Site
    Paris, 75012, France
    Recruiting
  • GSK Investigational Site
    Paris, 75013, France
    Recruiting
  • GSK Investigational Site
    Paris, 75018, France
    Recruiting
  • GSK Investigational Site
    Frankfurt am Main, Hesse 60590, Germany
    Recruiting
  • GSK Investigational Site
    Berlin, 10787, Germany
    Recruiting
  • GSK Investigational Site
    Cologne, 50937, Germany
    Recruiting
  • GSK Investigational Site
    Hamburg, 20146, Germany
    Recruiting
  • GSK Investigational Site
    München, 80337, Germany
    Recruiting
  • GSK Investigational Site
    Milan, MI 20122, Italy
    Recruiting
  • GSK Investigational Site
    Roma, RM 00168, Italy
    Recruiting
  • GSK Investigational Site
    Bergamo, 24127, Italy
    Recruiting
  • GSK Investigational Site
    Milan, 20127, Italy
    Recruiting
  • GSK Investigational Site
    Milan, 20142, Italy
    Recruiting
  • GSK Investigational Site
    Milan, 20157, Italy
    Recruiting
  • GSK Investigational Site
    Roma, 00149, Italy
    Recruiting
  • GSK Investigational Site
    Fukuoka, 810-8563, Japan
    Recruiting
  • GSK Investigational Site
    Kanagawa, 221-0855, Japan
    Recruiting
  • GSK Investigational Site
    Okinawa, 901-2725, Japan
    Recruiting
  • GSK Investigational Site
    Osaka, 534-0021, Japan
    Recruiting
  • GSK Investigational Site
    Osaka, 540-0006, Japan
    Recruiting
  • GSK Investigational Site
    Tokyo, 108-8639, Japan
    Recruiting
  • GSK Investigational Site
    Tokyo, 160-0023, Japan
    Recruiting
  • GSK Investigational Site
    Tokyo, 162-8655, Japan
    Recruiting
  • GSK Investigational Site
    Bydgoszcz, 85-030, Poland
    Recruiting
  • GSK Investigational Site
    Gdansk, 80-405, Poland
    Recruiting
  • GSK Investigational Site
    Porto, 4099-001, Portugal
    Recruiting
  • GSK Investigational Site
    Porto, 4200-319, Portugal
    Recruiting
  • GSK Investigational Site
    Vila Nova de Gaia, 4434-502, Portugal
    Recruiting
  • GSK Investigational Site
    Daegu, 700-721, South Korea
    Recruiting
  • GSK Investigational Site
    Gwangju, 61469, South Korea
    Recruiting
  • GSK Investigational Site
    Pusan, 49241, South Korea
    Recruiting
  • GSK Investigational Site
    Seoul, 03722, South Korea
    Recruiting
  • GSK Investigational Site
    Badalona, Barcelona 08916, Spain
    Recruiting
  • GSK Investigational Site
    Sant Boi de Llobregat, Barcelona 08830, Spain
    Recruiting
  • GSK Investigational Site
    A Coruña, 15006, Spain
    Recruiting
  • GSK Investigational Site
    Alicante, 03010, Spain
    Recruiting
  • GSK Investigational Site
    Almería, 04009, Spain
    Recruiting
  • GSK Investigational Site
    Barcelona, 08003, Spain
    Recruiting
  • GSK Investigational Site
    Barcelona, 08035, Spain
    Recruiting
  • GSK Investigational Site
    Barcelona, 08036, Spain
    Recruiting
  • GSK Investigational Site
    Barcelona, 08040, Spain
    Recruiting
  • GSK Investigational Site
    Barcelona, 08041, Spain
    Recruiting
  • GSK Investigational Site
    Elche Alicante, 03203, Spain
    Recruiting
  • GSK Investigational Site
    Getafe, 28905, Spain
    Recruiting
  • GSK Investigational Site
    Granada, 18014, Spain
    Recruiting

Showing the first 100 of 125 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Sudy Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.viiv-studyregister.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Oct 2027, 20 months after the start.

Of 34 industry-sponsored phase 2 interventional studies under HIV Infections, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's planned 20 months is close to that.

Counting every sponsor, half of 99 studies reached it within 31 months; a quarter within 17 and three quarters within 58.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jun 2027 → Oct 2027 and completion May 2028 → Jul 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2025
First posted
Oct 2, 2025
StartActual
Feb 11, 2026
Primary completionEst.
Oct 28, 2027was Jun 2027
CompletionEst.
Jul 9, 2032was May 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added, 6 sites removed. GSK Investigational Site is now Completed
Show 8 added (2 France, 2 Italy, 2 Spain, 1 Belgium, 1 Germany)
  • GSK Investigational Site · Ghent, Belgium
  • GSK Investigational Site · Paris, France
  • GSK Investigational Site · Paris, France
  • GSK Investigational Site · Frankfurt am Main, Germany
  • GSK Investigational Site · Milan, Italy
  • GSK Investigational Site · Roma, Italy
  • GSK Investigational Site · Badalona, Spain
  • GSK Investigational Site · Sant Boi de Llobregat, Spain
Show 6 removed
  • GSK Investigational Site · Ghent, Belgium
  • GSK Investigational Site · Frankfurt, Germany
  • GSK Investigational Site · Milan, Italy
  • GSK Investigational Site · Roma, Italy
  • GSK Investigational Site · Badalona, Spain
  • GSK Investigational Site · HebrOn, Spain
Nov 12, 2026
Primary completion
Jun 11, 2027→Oct 28, 2027
Nov 12, 2026
Study completion
May 22, 2028→Jul 9, 2032
Nov 12, 2026
Site contacts
Changed at 9 sites. See the sites
Show 9 sites
  • GSK Investigational Site · Louisville, United StatesContact removed G•••@gsk.com · •••3718Contact removed G•••@gsk.com · •••4466Contact removed (no phone or email listed)
  • GSK Investigational Site · Kansas City, United StatesContact person changed (no phone or email listed)
  • GSK Investigational Site · Buenos Aires, ArgentinaContact person changed (no phone or email listed)
  • GSK Investigational Site · Paris, FranceContact person changed (no phone or email listed)Contact person changed (no phone or email listed)
  • GSK Investigational Site · Milan, ItalyContact person changed (no phone or email listed)Contact person changed (no phone or email listed)Contact person changed (no phone or email listed)
  • GSK Investigational Site · Barcelona, SpainContact person changed (no phone or email listed)Contact person changed (no phone or email listed)Contact person changed (no phone or email listed)
  • GSK Investigational Site · Madrid, SpainContact person changed (no phone or email listed)
  • GSK Investigational Site · Marbella, SpainContact person changed (no phone or email listed)
  • GSK Investigational Site · Seville, SpainContact person changed (no phone or email listed)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    8 sites added, 6 sites removed. GSK Investigational Site is now Completed
    Show 8 added (2 France, 2 Italy, 2 Spain, 1 Belgium, 1 Germany)
    • GSK Investigational Site · Ghent, Belgium
    • GSK Investigational Site · Paris, France
    • GSK Investigational Site · Paris, France
    • GSK Investigational Site · Frankfurt am Main, Germany
    • GSK Investigational Site · Milan, Italy
    • GSK Investigational Site · Roma, Italy
    • GSK Investigational Site · Badalona, Spain
    • GSK Investigational Site · Sant Boi de Llobregat, Spain
    Show 6 removed
    • GSK Investigational Site · Ghent, Belgium
    • GSK Investigational Site · Frankfurt, Germany
    • GSK Investigational Site · Milan, Italy
    • GSK Investigational Site · Roma, Italy
    • GSK Investigational Site · Badalona, Spain
    • GSK Investigational Site · HebrOn, Spain
    Primary completion Jun 11, 2027→Oct 28, 2027
    Study completion May 22, 2028→Jul 9, 2032
    Site contacts Changed at 9 sites. See the sites
    Show 9 sites
    • GSK Investigational Site · Louisville, United StatesContact removed G•••@gsk.com · •••3718Contact removed G•••@gsk.com · •••4466Contact removed (no phone or email listed)
    • GSK Investigational Site · Kansas City, United StatesContact person changed (no phone or email listed)
    • GSK Investigational Site · Buenos Aires, ArgentinaContact person changed (no phone or email listed)
    • GSK Investigational Site · Paris, FranceContact person changed (no phone or email listed)Contact person changed (no phone or email listed)
    • GSK Investigational Site · Milan, ItalyContact person changed (no phone or email listed)Contact person changed (no phone or email listed)Contact person changed (no phone or email listed)
    • GSK Investigational Site · Barcelona, SpainContact person changed (no phone or email listed)Contact person changed (no phone or email listed)Contact person changed (no phone or email listed)
    • GSK Investigational Site · Madrid, SpainContact person changed (no phone or email listed)
    • GSK Investigational Site · Marbella, SpainContact person changed (no phone or email listed)
    • GSK Investigational Site · Seville, SpainContact person changed (no phone or email listed)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07202546
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Oct 2, 2025
Start date
Feb 11, 2026
Primary completion
Oct 28, 2027 (estimated)
Completion
Jul 9, 2032 (estimated)
Last update
Nov 12, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VH4524184

Start the discussion